Azithromycin
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Community Acquired Pneumonia (CAP)
Conditions
Community Acquired Pneumonia (CAP)
Trial Timeline
Feb 1, 2009 → Mar 1, 2010
NCT ID
NCT00809328About Azithromycin
Azithromycin is a phase 3 stage product being developed by Pfizer for Community Acquired Pneumonia (CAP). The current trial status is completed. This product is registered under clinical trial identifier NCT00809328. Target conditions include Community Acquired Pneumonia (CAP).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002089 | Pre-clinical | Completed |
| NCT00002309 | Pre-clinical | Completed |
| NCT00002344 | Phase 1 | Completed |
| NCT00002082 | Pre-clinical | Completed |
| NCT00002139 | Phase 1 | Completed |
| NCT00002328 | Pre-clinical | Completed |
| NCT00002085 | Pre-clinical | Completed |
| NCT00002090 | Pre-clinical | Completed |
| NCT01919996 | Phase 2 | Terminated |
| NCT00871494 | Phase 3 | Completed |
| NCT00809328 | Phase 3 | Completed |
| NCT00939185 | Pre-clinical | Completed |
| NCT00229944 | Phase 3 | Completed |
| NCT01227395 | Pre-clinical | Completed |
| NCT00599079 | Approved | Completed |
Competing Products
17 competing products in Community Acquired Pneumonia (CAP)